Navigation Links
Alimera Sciences' Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
Date:4/8/2009

vitreal injection, a procedure commonly employed by retinal specialists.

Currently, nearly 24 million people, or 8 percent of the population, in the U.S. have diabetes. Over time, all diabetics are at risk of developing some form of diabetic retinopathy, an ophthalmic condition of diabetes. In the U.S., diabetic retinopathy causes approximately 12,000 to 24,000 new cases of blindness each year, making diabetes the leading cause of new cases of blindness in adults aged 20 to 74. Based on published data, Alimera estimates that there are as many as 300,000 new cases of DME each year and 1,000,000 people have DME. There are no ophthalmic drug therapies currently approved by the U.S. Food and Drug Administration for the treatment of DME.

About Alimera Sciences, Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(TM), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has acquired options to exclusive, worldwide licenses for two classes of nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxi
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
2. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
3. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
4. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
6. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
7. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
8. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
9. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
10. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Reportlinker.com announces that a new ... Asia-Pacific Infusion Therapy Device Market ... Abstract: The Asia-Pacific ... infusion pumps, syringe infusion pumps, disposable infusion pumps, ... categories are segmented based on the type of ...
(Date:9/2/2014)... The Pharmaceutical Care Management Association (PCMA), the national association ... lawsuit in Iowa federal court ... law that restricts tools used by PBMs to lower ... The law—HF 2297—forces PBMs to overpay ... Maximum Allowable Cost (MAC) lists that keep generic drug ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
Breaking Medicine Technology:Asia-Pacific Infusion Therapy Device Market 2Asia-Pacific Infusion Therapy Device Market 3Asia-Pacific Infusion Therapy Device Market 4Asia-Pacific Infusion Therapy Device Market 5Asia-Pacific Infusion Therapy Device Market 6Asia-Pacific Infusion Therapy Device Market 7Asia-Pacific Infusion Therapy Device Market 8Asia-Pacific Infusion Therapy Device Market 9Asia-Pacific Infusion Therapy Device Market 10Asia-Pacific Infusion Therapy Device Market 11Asia-Pacific Infusion Therapy Device Market 12Asia-Pacific Infusion Therapy Device Market 13Asia-Pacific Infusion Therapy Device Market 14Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... Oct. 20 Premier Research Group Limited, the international ... of Bernard Sweeney as Executive Director, Medical Devices. In ... in the operations, strategic planning, and corporate development of ... will be based in Premier Research,s Swiss office. , ...
... 20 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... Investor Conference at 11:30 a.m. Pacific Time on October ... San Diego, California. , ISTA,s Chief Financial Officer, Lauren ... and clinical progress. To access the live audio broadcast, ...
Cached Medicine Technology:Premier Research Names Bernard Sweeney as Executive Director, Medical Devices 2
(Date:9/2/2014)... Germany, September 2, 2014 In a large ... researchers found that mild cognitive impairment (MCI) occurred ... mellitus type 2. Interestingly, this strong association was ... in older participants (66-80 years) the association vanished. ... of Alzheimer,s Disease . , The concept of ...
(Date:9/2/2014)... Melbourne, Australia (PRWEB) September 03, 2014 ... Australia attend to millions of people annually, arranging care ... subdivision's not-for-profit and private enterprises are expected to derive ... government funding, donations and private income. Over the five ... at an annualised rate of 6.6%, including growth of ...
(Date:9/2/2014)... Steven Reinberg HealthDay ... A device intended to help with weight loss by blocking ... meet expectations in a trial among obese patients. Using ... the brain and stomach, researchers hoped to suppress feelings of ... anticipated. "A device that safely blocks the nerve that ...
(Date:9/2/2014)... Doctors trained in locations with less intensive (and expensive) ... clinical decisions that spare patients unnecessary and excessive medical ... Internal Medicine . , "Growing concern about the costs ... assessing physicians, ability to avoid the provision of unnecessary ... Outcomes Group and The Dartmouth Institute for Health ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated ... of a luxurious line of graduated compression socks with natural ... COTTON Socks are joining the SIGVARIS MEDICAL collection for those ... comfort of natural cotton fibers. , “When people step ... find socks as soft as the finest cashmere,” says Clay ...
Breaking Medicine News(10 mins):Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2
... a few millimeters, depends on a supply of nutrients ... vascular wall cells of neighboring blood vessels to sprout ... blood circulation. , This process called angiogenesis involves ... receptors on the vascular wall cells. The departments of ...
... birds in the tropics look like they,re a drag to ... experiments by University of California, Berkeley, biologists shows that they ... at least in hummingbirds. , "We estimate that having a ... to 3 percent, which means the bird has to visit ...
... will help 5,000 more impoverished children in ... 2009 Best Picture "Slumdog Millionaire" shines the ... in India. Children International answers ... center to help poor children in Calcutta.To ...
... RALEIGH, N.C., March 12 MedThink Communications, a ... doctorate-level associate scientific director to support its rapidly ... two scientific directors at MedThink who provide high-level ... clients. With a team of seven doctorate-level medical ...
... study finds , , THURSDAY, March 12 (HealthDay News) ... testing athletes, because current tests ignore important ethnic ... and other hormones that increase testosterone levels are ... used in sports, according to the World Anti-Doping ...
... Highlights- Revenue: $35.7 million, up 19% from $29.9 million ... Q4,07LAWRENCE, Mass., March 12 NxStage Medical, Inc. (Nasdaq: ... dialysis products, today reported financial results for the three ... included revenue and Adjusted EBITDA results above the top ...
Cached Medicine News:Health News:A new measure for the malignancy of melanoma 2Health News:Long, sexy tails not a drag on male birds 2Health News:Long, sexy tails not a drag on male birds 3Health News:Long, sexy tails not a drag on male birds 4Health News:Photos: Children International Opens Center to Help Poor Children in India 2Health News:MedThink Hires Associate Scientific Director to Support Its Growing Health Care Clientele 2Health News:European Researchers Call for New Doping Standards 2Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 9Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 10Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 11
Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...
Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Colloidal Gold Conjugated, Protein A - 12 OD...
Medicine Products: